Flor Duarte, Calvão Joana A, Pratas Edgar, Coutinho Inês, Cardoso Jose C
Dermatology, Coimbra Local Health Unit, Coimbra, PRT.
Oncology, Coimbra Local Health Unit, Coimbra, PRT.
Cureus. 2024 Sep 21;16(9):e69870. doi: 10.7759/cureus.69870. eCollection 2024 Sep.
Scleroderma-like cutaneous sclerosis has been reported as a rare adverse reaction to several drugs, including the chemotherapeutical agent paclitaxel, used in therapeutic regimens for several malignancies. The sclerosis is usually limited to the skin, most commonly presenting in the lower limbs after weeks to months of therapy but is often refractory to treatment and progresses even after discontinuation of the offending agents, with significant resulting morbidity. We report a rare case of severe cutaneous sclerosis secondary to chemotherapy with nab-paclitaxel and gemcitabine, which did not respond to treatment and led to discontinuation of chemotherapy.
硬皮病样皮肤硬化症已被报道为几种药物罕见的不良反应,这些药物包括用于多种恶性肿瘤治疗方案的化疗药物紫杉醇。这种硬化通常局限于皮肤,最常见于治疗数周数月后的下肢,但往往对治疗无效,甚至在停用致病药物后仍会进展,导致严重的发病情况。我们报告一例罕见的严重皮肤硬化症病例,继发于纳米白蛋白结合型紫杉醇和吉西他滨化疗,该病例对治疗无反应,导致化疗中断。